22.95 +0.02 (0.09%)
After hours: 4:41PM EDT
|Bid||22.95 x 3000|
|Ask||23.09 x 1100|
|Day's range||22.93 - 23.33|
|52-week range||10.85 - 33.24|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||20.43|
On July 13, the FDA announced a voluntary recall of drugs containing valsartan and valsartan/hydrochlorothiazide API (active pharmaceutical ingredient) manufactured by Solco Healthcare, Major Pharmaceuticals, and Teva Pharmaceutical (TEVA). The drugs are used for the treatment of heart failure and high blood pressure.
Demand for generic drugs is on the rise, and investors are convinced the trend will keep this profitable company moving in the right direction.
On July 9, Teva announced the launch of its generic Uceris (budesonide) extended-release tablets (nine milligrams) in the United States. In November 2017, Teva prevailed in its litigation challenging Valeant Pharmaceuticals’ (VRX) Uceris patent, which was acquired through the acquisition of Salix in 2015. Teva was the first applicant to file an ANDA (abbreviated new drug application) for generic Uceris.
TRENTON, N.J. (AP) — In a story July 6 about Teva Pharmaceuticals moving its U.S. headquarters to New Jersey, The Associated Press erroneously reported the amount in tax credits the firm is receiving. The state's Economic Development authority approved about $40 million in credits over 10 years, not about $4 million in total credits over that period.
As we saw in the previous part of this series, Teva presented new data on fremanezumab at the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco. It is one of Teva’s key pipeline drugs and is expected to be a key growth driver for the company. Teva’s specialty products pipeline is provided in the graph below.
During the AHS (American Headache Society) 60th Annual Scientific Meeting in San Francisco, which was held from June 28 to July 1, Teva presented new data on its much-awaited migraine drug fremanezumab. Teva has a September PDUFA (Prescription Drug User Fee Act) date for the drug. On June 15, the company provided an update on the drug’s Enforce Phase 3 clinical development program for cluster headaches.
On July 5, Teva Pharmaceutical Industries (TEVA) stock ended the trading day at $23.92, a fall of 3.2% compared to the previous day. TEVA stock was trading 121% higher than its 52-week low of $10.85 on November 2, 2017. Currently, Teva Pharmaceutical stock is trading higher than its 50-day moving average of $22.56 as well as its 200-day moving average of $19.85.
Teva Pharmaceutical Industries (TEVA) is one of the largest generic drug manufacturers. It has been recuperating from its recent troubles as it started facing generic competition for its key product Copaxone. Warren Buffet’s Berkshire Hathaway initiated investment in Teva in the previous quarter and increased it in the recently reported quarter.
Today, Teva Pharmaceutical Industries (TEVA) announced that it will present new data for its migraine drug Fremanezumab, which is under review by the FDA for the preventive treatment as a monthly or quarterly injection, at the AHS’s (American Headache Society) 60th Annual Scientific Meeting in San Francisco. The event is being held from June 28 to July 1. Teva plans to present 23 abstracts, three oral presentations, and one late-breaking poster of Fremanezumab.
On June 11, Leerink raised its 12-month target price on Teva from $13 to $16 while maintaining its “underperform” rating on the stock. Leerink analyst Ami Fadia revised the target prices to better reflect the improving dynamics of the company.
Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.
Teva Pharmaceutical Industries (TEVA) is the largest generics pharma manufacturer in the world. In particular, the FDA is approving generics versions of branded drugs more rapidly to shift toward a more affordable healthcare structure. Teva is on track to achieve targeted cost reductions and revenue growth.
Alder Biopharmaceuticals gapped up Friday after rival Teva Pharmaceutical scrapped a late-stage study in chronic cluster headaches.
Teva Pharmaceutical’s (TEVA) fremanezumab is a key product awaiting FDA approval. The drug is also under Phase 2 trials for the treatment of post-traumatic headache and a Phase 3 trial for the treatment of cluster headache. The drug is expected to generate significant sales for the company in the years ahead. Teva’s specialty products pipeline is shown in the chart below.
On June 13, Teva Pharmaceutical Industries (TEVA) ended the trading day at a closing price of $24.33. TEVA stock was trading ~28.0% lower than its 52-week high of $33.80 reported on July 13, 2017. Currently, TEVA stock is trading higher than its 50-day moving average of $20.52 as well as its 200-day moving average of $19.05.
Shares of Teva Pharmaceutical Industries Ltd. dropped 1.4% in premarket trade Friday, after the drug maker said it will discontinue the phase 3 trial of its treatment for chronic cluster headaches, after ...
On June 13, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 8.8x, compared to the industry average PE of 12.3x. The company’s forward EV-to-EBITDA, which is a capital structure–neutral valuation measure, is 11.2x. This multiple is higher than the industry average of 10.3x.
Teva Pharmaceutical Industries (TEVA) has been in the news lately and is one of the most keenly watched stocks on Wall Street. Teva Pharmaceutical has reported positive developments with respect to its restructuring plan to restore its falling sales. On June 13, Reuters surveyed 29 analysts covering Teva.
As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a non-GAAP EPS of $0.88 on revenues of ~$2.0 billion during the first quarter. Valeant had a 5.4% decline in its year-over-year revenues during the first quarter due to a 9% decrease in operating revenues. The decrease was partially offset by the favorable impact of foreign exchange—compared to revenues of ~$2.1 billion during the first quarter of 2017.